ClinicalTrialsFinder

PIK3CA-Related Overgrowth Spectrum (PROS) Clinical Trials in Guangzhou, Guangdong

1 recruitingGuangzhou, Guangdong, China

Showing 1–1 of 1 trials

Recruiting
Phase 1Phase 2

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)

PIK3CA-Related Overgrowth Spectrum (PROS)PIK3CA-related Vascular Malformations (PRVM)
Haihe Biopharma Co., Ltd.141 enrolled15 locationsNCT06975618